Unknown

Dataset Information

0

A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.


ABSTRACT: OBJECTIVE:Menopausal vasomotor symptoms (VMS) may result from altered thermoregulatory control in brain regions innervated by neurokinin 3 receptor-expressing neurons. This phase 2b study evaluated seven dosing regimens of fezolinetant, a selective neurokinin 3 receptor antagonist, as a nonhormone approach for the treatment of VMS. METHODS:Menopausal women aged >40-65 years with moderate/severe VMS (?50?episodes/wk) were randomized (double-blind) to fezolinetant 15, 30, 60, 90?mg BID or 30, 60, 120?mg QD, or placebo for 12 weeks. Primary outcomes were reduction in moderate/severe VMS frequency and severity ([number of moderate VMS ×?2] + [number of severe VMS ×?3]/total daily moderate/severe VMS) at weeks 4 and 12. Response (?50% reduction in moderate/severe VMS frequency) was a key secondary outcome. RESULTS:Of 352 treated participants, 287 completed the study. Fezolinetant reduced moderate/severe VMS frequency by -1.9 to -3.5/day at week 4 and -1.8 to -2.6/day at week 12 (all P?

SUBMITTER: Fraser GL 

PROVIDER: S-EPMC7147405 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.

Fraser Graeme L GL   Lederman Samuel S   Waldbaum Arthur A   Kroll Robin R   Santoro Nanette N   Lee Misun M   Skillern Laurence L   Ramael Steven S  

Menopause (New York, N.Y.) 20200401 4


<h4>Objective</h4>Menopausal vasomotor symptoms (VMS) may result from altered thermoregulatory control in brain regions innervated by neurokinin 3 receptor-expressing neurons. This phase 2b study evaluated seven dosing regimens of fezolinetant, a selective neurokinin 3 receptor antagonist, as a nonhormone approach for the treatment of VMS.<h4>Methods</h4>Menopausal women aged >40-65 years with moderate/severe VMS (≥50 episodes/wk) were randomized (double-blind) to fezolinetant 15, 30, 60, 90 mg  ...[more]

Similar Datasets

| S-EPMC6554911 | biostudies-literature
| S-EPMC7709922 | biostudies-literature
| S-EPMC10551868 | biostudies-literature
| S-EPMC10026946 | biostudies-literature
| S-EPMC3246091 | biostudies-literature
| S-EPMC7188053 | biostudies-literature
| S-EPMC8372662 | biostudies-literature
| S-EPMC2518020 | biostudies-other
| S-EPMC9970022 | biostudies-literature